rhizocticin a profile

rhizocticin A: isolated from Bacillus subtilis ATCC 6633; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	14061801
CHEMBL ID	2415100
CHEBI ID	81400
MeSH ID	M0176091

Synonym
rhizocticin a
114301-25-6
C17944
CHEMBL2415100
chebi:81400 ,
l-arginyl-l-2-amino-5-phosphono-3z-pentenoic acid
(z,2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-phosphonopent-3-enoic acid
Q27155333
DTXSID101200234
l-norvaline, l-arginyl-3,4-didehydro-5-phosphono-, (3z)-
AKOS040747382

Drug Classes (1)

Class	Description
peptide	Amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another with formal loss of water. The term is usually applied to structures formed from alpha-amino acids, but it includes those derived from any amino carboxylic acid. X = OH, OR, NH2, NHR, etc.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (9)

Assay ID	Title	Year	Journal	Article
AID765014	Antifungal activity against Candida albicans at 3.5 to 1050 ug/L after 24 hrs by YNB medium disc diffusion method in absence of amino acids	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Synthesis and biological evaluation of potential threonine synthase inhibitors: Rhizocticin A and Plumbemycin A.
AID765020	Antifungal activity against Saccharomyces cerevisiae at 3.5 to 1050 ug/L after 24 hrs by malt extract medium disc diffusion method	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Synthesis and biological evaluation of potential threonine synthase inhibitors: Rhizocticin A and Plumbemycin A.
AID765019	Antifungal activity against Candida glabrata at 3.5 to 1050 ug/L after 24 hrs by malt extract medium disc diffusion method	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Synthesis and biological evaluation of potential threonine synthase inhibitors: Rhizocticin A and Plumbemycin A.
AID765021	Antifungal activity against Candida albicans at 3.5 to 1050 ug/L after 24 hrs by malt extract medium disc diffusion method	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Synthesis and biological evaluation of potential threonine synthase inhibitors: Rhizocticin A and Plumbemycin A.
AID765012	Antifungal activity against Candida glabrata at 3.5 to 1050 ug/L after 24 hrs by YNB medium disc diffusion method in absence of amino acids	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Synthesis and biological evaluation of potential threonine synthase inhibitors: Rhizocticin A and Plumbemycin A.
AID765013	Antifungal activity against Saccharomyces cerevisiae at 3.5 to 1050 ug/L after 24 hrs by YNB medium disc diffusion method in absence of amino acids	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Synthesis and biological evaluation of potential threonine synthase inhibitors: Rhizocticin A and Plumbemycin A.
AID765027	Antifungal activity against Saccharomyces cerevisiae at 3.5 to 1050 ug/L after 24 hrs by microdilution method	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Synthesis and biological evaluation of potential threonine synthase inhibitors: Rhizocticin A and Plumbemycin A.
AID765028	Antifungal activity against Candida albicans at 3.5 to 1050 ug/L after 24 hrs by microdilution method	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Synthesis and biological evaluation of potential threonine synthase inhibitors: Rhizocticin A and Plumbemycin A.
AID765026	Antifungal activity against Candida glabrata at 3.5 to 1050 ug/L after 24 hrs by microdilution method	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Synthesis and biological evaluation of potential threonine synthase inhibitors: Rhizocticin A and Plumbemycin A.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	2 (33.33)	18.2507
2000's	2 (33.33)	29.6817
2010's	2 (33.33)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.47 (24.57)
Research Supply Index	1.95 (2.92)
Research Growth Index	4.42 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.47)

All Compounds (24.57)

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (16.67%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (83.33%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
aminolevulinic acid Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.. 5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.	2.01	1	4-oxo monocarboxylic acid; amino acid zwitterion; delta-amino acid	antineoplastic agent; dermatologic drug; Escherichia coli metabolite; human metabolite; mouse metabolite; photosensitizing agent; plant metabolite; prodrug; Saccharomyces cerevisiae metabolite
2-amino-5-phosphonovalerate 2-Amino-5-phosphonovalerate: The D-enantiomer is a potent and specific antagonist of NMDA glutamate receptors (RECEPTORS, N-METHYL-D-ASPARTATE). The L form is inactive at NMDA receptors but may affect the AP4 (2-amino-4-phosphonobutyrate; APB) excitatory amino acid receptors.	2.42	2	non-proteinogenic alpha-amino acid	NMDA receptor antagonist
aspartic acid Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.. aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent. L-aspartic acid : The L-enantiomer of aspartic acid.	2.01	1	aspartate family amino acid; aspartic acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; mouse metabolite; neurotransmitter
threonine Threonine: An essential amino acid occurring naturally in the L-form, which is the active form. It is found in eggs, milk, gelatin, and other proteins.. threonine : An alpha-amino acid in which one of the hydrogens attached to the alpha-carbon of glycine is substituted by a 1-hydroxyethyl group.	1.98	1	amino acid zwitterion; aspartate family amino acid; L-alpha-amino acid; proteinogenic amino acid; threonine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
azoxybacilin azoxybacilin: an azoxy-containing antibiotic; produced by Bacillus cereus; structure given in first source. azoxybacilin : A non-proteinogenic alpha-amino acid that is (2S)-2-aminobutanoic acid substituted by a (Z)-methyl-NNO-azoxy moiety at position 4. It is an antibiotic isolated from the culture broth of Bacillus cereus and exhibits antifungal activity.	2.01	1
2-amino-5-phosphono-3-pentenoic acid 2-amino-5-phosphono-3-pentenoic acid: structure given in first source; RN given refers to (Z-(+-))-isomer	2.42	2
2-amino-5-hydroxy-4-oxopentanoic acid 2-amino-5-hydroxy-4-oxopentanoic acid: isolated from Streptomyces	2.01	1

rhizocticin a

Description

Cross-References

Synonyms (11)

Drug Classes (1)

Bioassays (9)

Research

Studies (6)

Market Indicators

Research Demand Index: 12.47

Study Types

rhizocticin a

Description

Cross-References

Synonyms (11)

Drug Classes (1)

Bioassays (9)

Research

Studies (6)

Market Indicators

Research Demand Index: 12.47

Study Types

Related Drugs (7)

Related Conditions (0)